J01F Macrolides, Lincosamides and Streptogramins: market analysis and determination of consumption in Ukraine for 2013-2019
DOI:
https://doi.org/10.24959/uekj.20.16Keywords:
antimicrobials, Macrolides, Lincosamides, Streptogramins, consumption, ATC/DDD methodology, market analysisAbstract
InUkraineup to 7 million cases of infectious diseases are recorded annually in particular caused by bacterial pathogens for example salmonella, shigella, campylobacter, Yersinia enterocolitica, meningococcus, gonococcus. A high incidence rate causes widespread use of antibiotic therapy. At the same time, both medical appointments and irresponsible self-medication form resistance to antimicrobial drugs. According to WHO 64 % of people around the world can self-medicate cold and flu with the use of antibacterial systemic drugs that are not indicated for such diseases. Antimicrobial resistance in theUnited Statesis about 3 million patients per year, which leads to death in 35 thousand of them.
Aim. To analyze the market inUkraine and calculate the consumption volumes of antimicrobial drugs of the J01F group Macrolides, Linkozamides, Streptogramins in the period of 2013-2019.
Results. According to WHO there are 19 INNs of antimicrobial drugs of the J01F group Macrolides, Lincosamides and Streptogramins, of which 15 INNs belong to the subgroup J01FA Macrolides, 2 INNs belong to the subgroup J01FF Linkosamides and 2 INNs belong to the subgroup J01FG Streptogramins. During the 7 studied years inUkraine only 9 INNs were present on the market: 7 INNs from the J01FA subgroup Macrolites, 2 INNs from the J01FF subgroup Lincosamides, none of the J01FG subgroup Streptogramins. The number of TNs of drugs of the J01F group in the pharmaceutical market ofUkraine ranged from 188 TNs in 2013 to136 in 2019. Using the ATC/DDD methodology in a 2013-2019 retrospective, it has been shown that hospital consumption of J01F group drugs in the period from 2016 to 2019 increased, and in 2018 there was a peak in consumption. The outpatient consumption of J01F drugs was 1.670051825 DID in 2013 and rose to 2.488815071 DID in 2019, but 6.1 % decrease in consumption in 2019 compared to 2018.
Conclusions. During the study period there was a reduction in the range of J01F group Macrolides, Lincosamides and Streptogramins drugs to 136 TNs with a simultaneous increase in the share of domestic drugs to 40.7 % of the range in 2019. Drugs of the Streptogramins subgroup are not represented on the domestic market. In the calculation of DID hospital consumption of Macrolides and Lincosamides increased 1.73 times in 2016-2019, outpatient – 1.47 times in 2013-2019, and in 2018 there was a peak in the consumption of these drugs.References
The world health report. (1996). Fighting disease, fostering development. Geneva: WHO, 143. Available at: https://www.who.int/whr/1996/en/whr96_en.pdf?ua=1 (date of access: 12.03.2020).
World health statistics. (2010). Geneva: WHO, 177. Available at: https://www.who.int/gho/publications/world_health_statistics/EN_WHS10_Full.pdf (date of access: 12.03.2020).
Projections of mortality and causes of death, 2016 to 2060. (n.d.). WHO. Available at: https://www.who.int/healthinfo/global_burden_disease/projections/en/ (date of access: 12.03.2020).
Infektsiina zakhvoriuvanist naselennia Ukrainy za hruden 2018 – hruden 2019 r. (2020). Tsentr hromadskoho zdorov’ia Ministerstva okhorony zdorov’ia Ukrainy. Available at: https://phc.org.ua/kontrol-zakhvoryuvan/inshi-infekciyni-zakhvoryuvannya/monitoring-i-ocinka/infekciyna-zakhvoryuvanist-naselennya-ukraini (date of access: 12.03.2020).
Antibiotic resistance: Multi-country public awareness survey. (2015). Geneva: WHO, 59 p.
Antibiotic Resistance Threats in the United States. (2019). CDC: Atlanta, 150 p.
Omura, Satoshi. (ed.). (2003). Macrolide Antibiotics: Chemistry, Biology, and Practice (2nd Edition). San Diego: Academic Press, 365.
Erythromycin, New and Promising Antibiotic. (1952). New England Journal of Medicine, 247(7), 267–269. https://doi.org/10.1056/nejm195208142470710
Nikolaienko, V. B. (2017). Infektsiini zakhvoriuvannia u ditei: antybiotykoterapiia, likuvannia respiratornykh infektsii ta helmintoziv. Ukrainskyi medychnyi chasopys, 1–3.
Maidannyk, V. H., Yemchynska, Ye. O. (2014). Klinichni nastanovy z diahnostyky ta likuvannia pozalikarnianoi pnevmonii u ditei z pozytsii dokazovoi medytsyny. Kyiv, 43.
Yakovleva, O. O. (ed.). (2011). Taktyka vyboru antybiotykiv: navch. posib. dlia stud. vyshch. med. navch. zakl., likariv-interniv ta simeinykh likariv (3-rd edition). Vinnytsia : Nova knyha, 224.
MacLeod, A. J., Ross, H. B., Ozere, R. L., Digout, G., van Rooyen C. E. (1964). Lincomycin: A New Antibiotic Active Against Staphylococci and Other Gram-Positive Cocci: Clinical and Laboratory Studies. Can Med Assoc J., 91, 1056–1060.
Neonatal Formulary: Drug Use in Pregnancy and the First Year of Life (7 edition). (2014). John Wiley & Sons, 162.
Bonfiglio, G., & Furneri, P. M. (2001). Novel streptogramin antibiotics. Expert Opinion on Investigational Drugs, 10(2), 185–198. https://doi.org/10.1517/13543784.10.2.185
Singh, S. B., Genilloud, O., & Peláez, F. (2010). Terrestrial Microorganisms – Filamentous Bacteria. Comprehensive Natural Products II, 109–140. https://doi.org/10.1016/b978-008045382-8.00036-8
Matyashova, N., & Iakovlieva, L. (2015). Analysis of consumption of macrolides in Ukraine. Clinical Pharmacy, 19(2), 19–22. https://doi.org/10.24959/cphj.15.1338
Korobova, Ye. S. (2017). Optymizatsiia farmatsevtychnoho zabezpechennia pilhovykh dytiachykh katehorii naselennia za umov reimbursatsii vartosti likarskykh zasobiv. Candidate’s thesis. Kharkiv, 381.
Shmatenko, O. P., Bielozorova, O. V. (2015). Analiz antybakterialnoi terapii u khirurhichnomu likuvanni viiskovosluzhbovtsiv postrazhdalykh v ATO z vykorystanniam kompleksnoho chastotnoho/AVS/VEN-analizu. Viiskova medytsyna Ukrainy, 15, 65–70.
Dronova, M. L. (2016). Farmakodynamichni osoblyvosti antybakterialnoi dii novykh pokhidnykh arylalifatychnykh aminospyrtiv. Candidate’s thesis. Kyiv, 192.
Systema doslidzhennia rynku likarskykh zasobiv «Farmstandart» kompanii «Morion». (n.d.). Available at: http://www.pharmstandart.com.ua
WHO Collaborating Centre for Drug Statistics Methodology. (n.d.). Available at: https://www.whocc.no/atc_ddd_index/ (date of access: 12.03.2020).
Morozov, A. M., Iakovlieva, L. V., Stepanenko, A. V. (2013). Vyvchennia spozhyvannia likarskykh zasobiv za anatomo-terapevtychno-khimichnoiu klasyfikatsiieiu ta vstanovlenymy dobovymy dozamy (ATC/DDDmetodolohiia): metod. rek. Kyiv: NFaU; DETs MOZ Ukrainy, 32.
Downloads
Published
Issue
Section
License
Copyright (c) 2020 National University of Pharmacy
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).